Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) was the recipient of a significant drop in short interest in January. As of January 12th, there was short interest totalling 1,331,591 shares, a drop of 9.1% from the December 29th total of 1,464,128 shares. Currently, 1.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 121,996 shares, the short-interest ratio is currently 10.9 days.
Matinas BioPharma (NYSEAMERICAN:MTNB) opened at $1.14 on Friday. The firm has a market cap of $105.96, a PE ratio of -3.08 and a beta of 0.69. Matinas BioPharma has a 52 week low of $1.01 and a 52 week high of $3.99.
Matinas BioPharma (NYSEAMERICAN:MTNB) last issued its earnings results on Wednesday, November 15th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. Matinas BioPharma had a negative net margin of 7,558.92% and a negative return on equity of 195.09%. The company had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.05 million.
TRADEMARK VIOLATION NOTICE: This news story was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2018/01/28/matinas-biopharma-holdings-inc-mtnb-sees-large-decrease-in-short-interest.html.
About Matinas BioPharma
Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.